Resources
Download this reportCombating Tuberculosis
Inside this issue
• Researchers are investigating the disease’s mechanism and genetics
• Video: Andrew Jack, FT pharmaceuticals correspondent, talks to experts
• Joint the debate at the FT Health Blog - -
Content
Complacency is one of the greatest risks
Andrew Jack finds scientific progress has been slow with too few targets met for this disease of the marginalised
Useful links to TB organisations
WHO information, resources for business, advocacy groups, R&D and treatment
Drug resistance: Treatment is too complex and too slow
Andrew Jack on why resistant strains are more prevalent
UK case study: Mobile X-rays can reach farther
Andrew Jack visits a unit in London that targets drug addicts and the homeless, who are among the most affected
Drugs: Fresh offensive combines several components
Researchers are investigating the disease mechanism and genetics, says Clive Cookson
Inoculations: Drive is on to replace venerable 90-year-old vaccine
Clive Cookson says ‘recombinant’ drugs aim to produce a stronger immune response than BCG
Diagnostics: Tests are of limited use without labs and skills
Detection techniques are improving in developing countries, says Sarah Murray
Guest column: Jorge Sampaio – private sector has a crucial role to play
Every corporation can make a real difference, writes Jorge Sampaio
Guest column: Archbishop Emeritus Desmond Tutu
The patron of TB Alert recounts his personal involvement with the disease, both as sufferer and campaigner, and issues a call for action
Guest Column: Craig David – voices against stigma
With a strong will and some serious determination, attitudes toward TB can be changed, writes Craig David
